[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545747":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":52,"centralContacts":57,"locations":63,"responsibleParty":309,"collaborators":36,"id":311,"slug":312,"hasResults":313,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":36,"eligibilityCriteria":317,"healthyVolunteers":313,"sex":318,"minAge":319,"maxAge":320,"enrollmentInfo":321,"targetDuration":36,"studyType":324,"phases":325,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":66,"whyStopped":36,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":347},{"fullName":5,"class":6},"Tyligand Pharmaceuticals (Suzhou) Limited","INDUSTRY",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1: Dose-finding\u002Fevaluation of TSN1611 monotherapy","EXPERIMENTAL","The phase 1 part will evaluate the prespecified sequential dose levels of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors to determine the recommended dose of TSN1611 for further investigation.",[13],"Drug: TSN1611",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 2: Dose expansion of TSN1611 monotherapy","Phase 2 part will evaluate the efficacy and safety of TSN1611 as monotherapy at the recommended dose level in separate groups of patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer, or other solid tumors, harboring KRAS G12D mutations.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Dose of Phase 1b\u002F2 part of TSN1611 combination therapy-Cohort A","Cohort A: TSN1611 combined with cetuximab treating subjects with advanced solid tumors harboring KRAS G12D mutation:",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Dose of Phase 1b\u002F2 part of TSN1611 combination therapy-Cohort B","Cohort B: TSN1611 combined with GnP regimen (i.e., gemcitabine and nab-paclitaxel) treating subjects with advanced PDAC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Dose of Phase 1b\u002F2 part of TSN1611 combination therapy-Cohort C","Cohort C: TSN1611 combined with cetuximab and mFOLFOX6 regimen (i.e., fluorouracil, leucovorin, oxaliplatin) treating subjects with advanced CRC with KRAS G12D mutation who received no prior systemic treatment in the advanced setting.",[13],[31,37,40,45],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","TSN1611","TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.",[9,15],null,{"type":32,"name":33,"description":38,"armGroupLabels":39,"otherNames":36},"TSN1611 BID, Cetuximab will be administered via intravenous infusion at a dose of 500 mg\u002Fm² every 2 weeks.",[19],{"type":32,"name":33,"description":41,"armGroupLabels":42,"otherNames":43},"TSN1611 BID, Paclitaxel (albumin-bound) at 125 mg\u002Fm² and gemcitabine at 1000 mg\u002Fm² will be administered via intravenous infusion on Days 1, 8, and 15 of each 4-week cycle.",[23],[44],"Paclitaxel (albumin-bound)",{"type":32,"name":33,"description":46,"armGroupLabels":47,"otherNames":48},"TSN1611 BID everyday and Patients will be administered with mFOLFOX6 on Days 1 and 2, every 2 weeks.",[27],[49,50,51],"Oxaliplatin injection","fluorouracil","leucovorin",[53],{"name":54,"affiliation":55,"role":56},"Cindy Li","Tyligand Bioscience (Shanghai) Limited","STUDY_DIRECTOR",[58],{"name":59,"role":60,"phone":61,"phoneExt":36,"email":62},"Tyligand Clinical Trial Info","CONTACT","+86 021-50720081","clinical_trial@tyligand.com",[64,81,93,106,122,135,148,161,175,191,205,218,232,245,254,264,276,287,298],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"MD Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":73,"coordinates":74},"Point",[75,76],-95.36327,29.76328,{"lat":76,"lon":75},[79],{"name":80,"role":60,"phone":36,"phoneExt":36,"email":36},"Siqing Fu, MD,PhD",{"facility":82,"status":66,"city":83,"state":68,"zip":84,"country":70,"countryCode":71,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"NEXT Oncology","San Antonio","78229",{"type":73,"coordinates":86},[87,88],-98.49363,29.42412,{"lat":88,"lon":87},[91],{"name":92,"role":60,"phone":36,"phoneExt":36,"email":36},"David Sommerhalder, MD",{"facility":94,"status":66,"city":95,"state":96,"zip":97,"country":70,"countryCode":71,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"NEXT Virginia","Fairfax","Virginia","22031",{"type":73,"coordinates":99},[100,101],-77.30637,38.84622,{"lat":101,"lon":100},[104],{"name":105,"role":60,"phone":36,"phoneExt":36,"email":36},"Alexander Spira, MD",{"facility":107,"status":66,"city":108,"state":109,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Anhui Provincial Cancer Hospital","Hefei","Anhui","China","CN",{"type":73,"coordinates":113},[114,115],117.28083,31.86389,{"lat":115,"lon":114},[118,120],{"name":119,"role":60,"phone":36,"phoneExt":36,"email":36},"Yueyin Pan",{"name":119,"role":121,"phone":36,"phoneExt":36,"email":36},"PRINCIPAL_INVESTIGATOR",{"facility":123,"status":66,"city":124,"state":125,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":126,"geoPoint":130,"contacts":131},"Beijing Cancer Hospital","Beijing","Beijing Municipality",{"type":73,"coordinates":127},[128,129],116.39723,39.9075,{"lat":129,"lon":128},[132,134],{"name":133,"role":60,"phone":36,"phoneExt":36,"email":36},"Minglei Zhuo",{"name":133,"role":121,"phone":36,"phoneExt":36,"email":36},{"facility":136,"status":66,"city":137,"state":138,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"The First Affiliated Hospital of Guangzhou Medical University","Guangzhou","Guangdong",{"type":73,"coordinates":140},[141,142],113.25,23.11667,{"lat":142,"lon":141},[145,147],{"name":146,"role":60,"phone":36,"phoneExt":36,"email":36},"Chengzhi Zhou",{"name":146,"role":121,"phone":36,"phoneExt":36,"email":36},{"facility":149,"status":66,"city":150,"state":151,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Hubei Cancer Hospital","Wuhan","Hubei",{"type":73,"coordinates":153},[154,155],114.26667,30.58333,{"lat":155,"lon":154},[158,160],{"name":159,"role":60,"phone":36,"phoneExt":36,"email":36},"Bin Yang",{"name":159,"role":121,"phone":36,"phoneExt":36,"email":36},{"facility":162,"status":66,"city":163,"state":164,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"Hunan Cancer Hospital","Changsha","Hunan",{"type":73,"coordinates":166},[167,168],112.97087,28.19874,{"lat":168,"lon":167},[171,173],{"name":172,"role":60,"phone":36,"phoneExt":36,"email":36},"Lin Wu, MD",{"name":174,"role":121,"phone":36,"phoneExt":36,"email":36},"Lin Wu",{"facility":176,"status":66,"city":177,"state":178,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"The First Affiliated Hospital of Nanchang University - Donghu District","Nanchang","Jiang",{"type":73,"coordinates":180},[181,182],115.85306,28.68396,{"lat":182,"lon":181},[185,187,189,190],{"name":186,"role":60,"phone":36,"phoneExt":36,"email":36},"Yong Li",{"name":188,"role":60,"phone":36,"phoneExt":36,"email":36},"Pu Li",{"name":186,"role":121,"phone":36,"phoneExt":36,"email":36},{"name":188,"role":121,"phone":36,"phoneExt":36,"email":36},{"facility":192,"status":66,"city":193,"state":194,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":195,"geoPoint":199,"contacts":200},"Linyi Cancer Hospital","Linyi","Shandong",{"type":73,"coordinates":196},[197,198],118.34278,35.06306,{"lat":198,"lon":197},[201,203],{"name":202,"role":60,"phone":36,"phoneExt":36,"email":36},"Janhua Shi",{"name":204,"role":121,"phone":36,"phoneExt":36,"email":36},"Jianhua Shi",{"facility":206,"status":66,"city":207,"state":208,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":209,"geoPoint":213,"contacts":214},"Shanghai Tenth People's Hospital","Shanghai","Shanghai Municipality",{"type":73,"coordinates":210},[211,212],121.45806,31.22222,{"lat":212,"lon":211},[215,217],{"name":216,"role":60,"phone":36,"phoneExt":36,"email":36},"Xiaojun Chen",{"name":216,"role":121,"phone":36,"phoneExt":36,"email":36},{"facility":219,"status":66,"city":220,"state":221,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":222,"geoPoint":226,"contacts":227},"West China Hospital, Sichuan University","Chengdu","Sichuan",{"type":73,"coordinates":223},[224,225],104.06667,30.66667,{"lat":225,"lon":224},[228,230],{"name":229,"role":60,"phone":36,"phoneExt":36,"email":36},"Ma Ji",{"name":231,"role":121,"phone":36,"phoneExt":36,"email":36},"Ji Ma",{"facility":233,"status":66,"city":234,"state":235,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":236,"geoPoint":240,"contacts":241},"Sir Run Run Shaw Hospital - Zhejiang University School of Med","Hangzhou","Zhejiang",{"type":73,"coordinates":237},[238,239],120.16142,30.29365,{"lat":239,"lon":238},[242,244],{"name":243,"role":60,"phone":36,"phoneExt":36,"email":36},"Haizhou Lou",{"name":243,"role":121,"phone":36,"phoneExt":36,"email":36},{"facility":246,"status":66,"city":234,"state":235,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":247,"geoPoint":249,"contacts":250},"The First Affiliated Hospital - Zhejiang University School of Medicine",{"type":73,"coordinates":248},[238,239],{"lat":239,"lon":238},[251,253],{"name":252,"role":60,"phone":36,"phoneExt":36,"email":36},"Jianya Zhou",{"name":252,"role":121,"phone":36,"phoneExt":36,"email":36},{"facility":255,"status":66,"city":234,"state":235,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":256,"geoPoint":258,"contacts":259},"The Second Affiliated Hospital of Zhejiang University School of Medicine",{"type":73,"coordinates":257},[238,239],{"lat":239,"lon":238},[260,262],{"name":261,"role":60,"phone":36,"phoneExt":36,"email":36},"Yuan Ying",{"name":263,"role":121,"phone":36,"phoneExt":36,"email":36},"Ying Yuan",{"facility":265,"status":66,"city":266,"state":235,"zip":36,"country":110,"countryCode":111,"cosmosGeoPoint":267,"geoPoint":271,"contacts":272},"Taizhou Hospital of Zhejiang Province","Taizhou",{"type":73,"coordinates":268},[269,270],121.43312,28.66266,{"lat":270,"lon":269},[273,275],{"name":274,"role":60,"phone":36,"phoneExt":36,"email":36},"Dongqing Lv",{"name":274,"role":121,"phone":36,"phoneExt":36,"email":36},{"facility":277,"status":66,"city":124,"state":36,"zip":278,"country":110,"countryCode":111,"cosmosGeoPoint":279,"geoPoint":281,"contacts":282},"Beijing Cancer Hospital, Beijing, China","100142",{"type":73,"coordinates":280},[128,129],{"lat":129,"lon":128},[283,285],{"name":284,"role":60,"phone":36,"phoneExt":36,"email":36},"Lin Shen",{"name":286,"role":121,"phone":36,"phoneExt":36,"email":36},"Lin Shen, MD",{"facility":288,"status":66,"city":207,"state":36,"zip":289,"country":110,"countryCode":111,"cosmosGeoPoint":290,"geoPoint":292,"contacts":293},"Shanghai Chest Hospital, Shanghai, China","200030",{"type":73,"coordinates":291},[211,212],{"lat":212,"lon":211},[294,296],{"name":295,"role":60,"phone":36,"phoneExt":36,"email":36},"Shun Lu",{"name":297,"role":121,"phone":36,"phoneExt":36,"email":36},"Shun Lu, MD",{"facility":299,"status":66,"city":207,"state":36,"zip":300,"country":110,"countryCode":111,"cosmosGeoPoint":301,"geoPoint":303,"contacts":304},"Shanghai Zhongshan Hospital, Shanghai, China","200032",{"type":73,"coordinates":302},[211,212],{"lat":212,"lon":211},[305,307],{"name":306,"role":60,"phone":36,"phoneExt":36,"email":36},"Tianshu Liu",{"name":308,"role":121,"phone":36,"phoneExt":36,"email":36},"Tianshu Liu, MD",{"type":310,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100545747","phase-1-a-study-of-tsn1611-treating-patients-with-advanced-solid-tumors-harboring-kras-g12d-mutation-100545747",false,"NCT06385925","A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","Phase 1\u002F2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation","Subjects must meet all the following inclusion criteria to be eligible for participation in this study:\n\n* The subject fully understands the requirements of the study and voluntarily signs the ICF.\n* At least 18 years of age at the time of informed consent.≤ 75 years of age for Cohort B and C.\n* Life expectancy of 3 months or more.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Phase 1 part (1a\u002F1b) of Monotherapy:\n\nSubjects with histologically or cytologically confirmed locally advanced or metastatic solid tumor harboring KRAS G12D mutation; subjects must be refractory or intolerable to standard treatment, or have no standard treatment available, or the subject is ineligible or declines standard treatment.\n\nPhase 2 part of TSN1611 Monotherapy:\n\nSubjects with histologically or cytologically confirmed locally advanced or metastatic PDAC、CRC and NSCLC harboring KRAS G12D mutation; According to the requirements of different combined cohorts, the number of previous treatments is taken into account.\n\n• Patients with adequate cardiac, liver, renal function, etc.\n\nExclusion Criteria\n\nSubjects will be excluded if they meet any of the following criteria:\n\n* Leptomeningeal disease or Active central nervous system (CNS) metastases.\n* Prior systemic anti-cancer treatment within 21 days or 5 half-lives (whichever is shorter will be used as the criteria) prior to the first dose of study drug.\n* Radical radiation within 4 weeks prior to the first dose of study drug; palliative radiotherapy within 1 week prior to the first dose of study drug.\n* Any unresolved Grade 2 or higher toxicity from previous anticancer therapy except alopecia.\n* Has participated in a study of investigational agent and received the investigational agent within 21 days or 5 half-lives, if known (whichever is shorter) prior to the first dose of study drug.\n* History of interstitial lung disease (ILD), drug induced IDL, or current active pneumonitis, radiation pneumonitis requiring therapeutic intervention, or uncontrolled other lung disease.\n* Any of the following in the past 6 months: myocardial infarction, unstable angina, symptomatic congestive heart failure, stroke or transient ischemic attack, pulmonary embolism.\n* Prior treatment with KRAS G12D targeted therapy.\n* Has a history or current evidence of any severe condition, concurrent therapy, or laboratory abnormality that might confound the interpretation of the study results, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the investigator.","ALL","18 Years","75 Years",{"count":322,"type":323},440,"ESTIMATED","INTERVENTIONAL",[326,327],"PHASE1","PHASE2","The study is a first-in-human (FIH), open-label, multi-center phase 1\u002F2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part. This study will evaluate the efficacy of TSN1611 at RP2D(s) through ORR using RECIST version 1.1, and determine and confirm the MTD\u002FRP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with gemcitabine and albumin-bound paclitaxel in subjects with selected solid tumors.",[330],"Malignant Neoplasm",[332,333,334,335,336,337],"solid tumor","KRAS G12D mutation","pancreatic cancer","colorectal cancer","non-small cell lung cancer","malignant neoplasm","2026-04-21",{"date":340,"type":341},"2026-04-24","ACTUAL",{"date":343,"type":341},"2024-04-29",{"date":345,"type":323},"2027-04-30",{"name":5,"class":6},19]